November 4, 2025 • 27 mins
Cravings fade, scales move, and blood sugar steadies—GLP-1 drugs promise a lot. We take you past the hype and into the real mechanics of how these medications work in the gut, the pancreas, and the brain. You’ll hear a clear, plain-English breakdown of glucagon-like peptide-1, why slowing gastric emptying increases fullness, and how glucose-dependent insulin release lowers A1C without the same hypoglycemia risk as older drugs. Then we zoom out to the brain: reward circuits, appetite signals, and the surprising ways long-term use can dampen drive for food and other rewards.
We also trace the modern arc from Ozempic’s diabetes approval to Wegovy’s obesity indication, and why tirzepatide’s dual-action profile captured headlines. That context matters for cost, insurance coverage, and the explosion of compounded products—some safe, some not. We outline a clinician-led plan that starts low and titrates slow, pairs medication with strength training and protein, and tracks labs like A1C, renal function, and thyroid history. The goal: powerful results without sacrificing muscle, motivation, or safety.
No sugarcoating the risks. Nausea, constipation, pancreatitis warnings, gallbladder events with rapid weight loss, dehydration-related kidney injury, and a boxed thyroid warning are all part of the picture. We explain who should avoid GLP-1s, what red flags call for urgent care, and why stopping the drug often brings weight regain unless habits change. If you’re considering GLP-1s for “sugar season” or beyond, this conversation helps you set realistic targets, protect lean mass, and navigate ethics and access with clarity. Subscribe, share with a friend who’s curious, and leave a review to tell us what you want us to explore next.
- Follow us on our social media on YouTube, Twitter, Facebook, Instagram, TikTok
- Check us out at FullLifeTampa.com
- Contact us at info@fulllifetampa.com
- Leave a review here
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
SPEAKER_00 (00:25):
Welcome to another episode of Living a Full Life.
I'm Dr.
Enrico Dolcecori.
And each and every week we dropyou health and wellness tips for
you and your family to livehealthier, fuller lives by
listening in.
And we appreciate each and everyone of you.
This week's topic, GLP1s.
We're getting into weight lossseason.
You know what that means.
New Year's resolutions, end ofthe year.
(00:47):
It's actually sugar season.
And I thought this was a perfecttime to talk about this stuff
because people actually startthinking about this now.
This is almost the busiest timeof the year for people thinking
about weight loss.
I think it's from a healthyperspective, from our
perspective in the functionalmedicine and chiropractic realm,
is that we get healthy,conscious people that are always
ahead of the game.
So they're not going to waittill January 1st for a
(01:09):
resolution.
They know it's sugar season.
They're like, what can I do tostay out of trouble?
And that's a great preventativeway to keep yourself healthy.
And I love it.
So what a great timing for this.
GLP ones have blown up.
I think uh Ozempik alone has uhdoubled Denmark's gross national
product, I mean uh GDP.
(01:30):
That's insane, insane.
It's like trillion, I thinkwe're approaching trillions, uh,
kid with an S on uh how muchmoney this stuff is made at
Ozempic and its you knowcompounds as well.
So let's talk about what GLPones are.
And you know how what I'm gonnatalk about.
I'm gonna talk about thephysiology, how it works, what
it does in the body, so you geta general understanding because
(01:51):
that's how I understand things.
So I guess if you listen to mypodcast, it's because we are on
the same wavelength.
If you don't, it's because I'meither way above your head or
way maybe too dumb for you.
I don't know, whatever it is.
But the people who listen doappreciate it.
And I try and keep it simple buteducational each and every week.
This might be one you want toshare with people thinking about
GLP1s, some aglutides, on it,not on it, maybe had adverse
(02:14):
reactions, whatever may be.
We're gonna talk about thisdiving into GLP1s.
They are a class of medicinesthat has exploded into everyday
conversation.
Uh, we'll explain what they are,how they work in the body and
the brain, where they come from,even yes, the history of the
Ozempic story, how they shouldand shouldn't be used, and the
(02:35):
risk patients need to know aboutusing them.
Whether you treat patients,maybe you're a provider, or
maybe you're thinking aboutusing these themselves, or
you're just curious about them.
Could they be good for me?
Could they be good for someone Iknow?
This episode gives you thescience and the practical
takeaways that I hope you learnsome stuff from.
So, what is GLP1?
What does that stand for?
(02:56):
It's glucagon-like peptide dashone.
It's nor it's created in thebody naturally, it's an
incertain hormone released fromthe gut after you eat.
So it's in the lining of thegut, of your stomach, of your
gut.
Once you eat and you start thedigestive process, it releases
this hormone and it enhancesglucose-dependent insulin
(03:20):
secretions.
So it suppresses glucagon, slowsgastric emptying, and reduces
appetite.
And that's a good recipe forhelping people digest their
food, keep blood glucose levelsgood, lowering A1C, and eating
less.
And when you do those fourthings, you tend to lose weight.
(03:41):
It's a great side effect.
So we'll get into the storylater.
Physiological mechanism, ifyou're wondering how this works
in the nitty-gritty, they'resecreted from intestinal L cells
in response to nutrients likeendogenous GLP1 acts on GLP1
receptors in the pancreas toinsul increase insulin only when
(04:03):
glucose is elevated.
So for those of us that areinsulin sensitive, uh, this
helps because it tells thepancreas, hey, there's we're
helping, we're nudging you here.
Don't don't slack on theinsulin.
Um, because over time, as welive with higher glucose levels
in the blood, our pancreasstarts to get lethargic.
(04:23):
It gets fatigued, it gets tired,and then it's a little bit less
receptive to glucose.
And so it's like, uh, do wereally need to pump and inject
insulin?
I've been doing this for 48years.
Do I really need to keep pumpingevery time you eat a meal?
What's up with you and your andyour um jellies and marmalades
on your toast, man?
Like, come on, why do I gotta dothis every morning, right?
(04:45):
So that's what's going on withthe pancreas.
So it increases it, makes itmore sensitive, and says, yeah,
man, you gotta do it.
It's like a personal trainer foryour pancreas.
Like, come on, do it, do yourjob.
And it does it, but only whenit's elevated.
So we get better control.
That glucose dependence reduceshypoglycemia risk compared with
other older drugs that we usefor maybe diabetes or
(05:05):
prediabetes that would justinject insulin into the body.
And when you do that, you got tomonitor the glucose levels.
And if we do too much insulin,it will lower blood glucose to a
hypoglycemic level, which canmake people faint, pass out, and
those things.
So, this has been better atdoing that for pre-diabetic
patients, not for strictlydiabetic patients.
(05:26):
It also suppresses glucagonrelease and slows gastric
emptying, which helps reducepost-meal glucose spikes and
increase satiety, increases yourfeeling of feeling full.
So pharmaceutical GLP1 receptoragonists, exotide, uh,
(05:48):
lyriclutide, semaglutide, allthese ones are modified to last
longer in the body so they canbe dosed daily or weekly and
achieve sustained effects onappetite and glycemic control.
Okay, there you go.
That's the physiologicalmechanism.
All receptors in the gut and thepancreas to help control glucose
(06:12):
levels in the body bycontrolling good output of
insulin.
There you go.
That's a summary of thephysiology.
How did GLP once alter the brainand behavior?
This is stuff people don't talkabout.
We talk about the physiology, wetalk about what they do,
suppress appetite, helps emptythe gut, helps do all this
stuff, and helps you eat lessand you lose weight.
(06:33):
And everyone's I'll take it,I'll buy it.
How much is it?
600 bucks a month, I'll do it.
And they do it.
But the truth is, is what is itdoing to your brain?
If we're going to talk abouthormone receptors binding and
competing for receptor sites inthe body, you have to involve
the brain.
The brain is gonna get involvedwith this.
So GLP1 receptors are present inmultiple brain regions, not just
(06:57):
one.
Hypothalamus, your brain stem,your mesolithic reward circuits,
it's they're everywhere.
So these GLP1 receptors are backand forth.
The gut brain connection.
We've talked about this many,many times.
And this medication, this drug,this peptide, is bringing it to
the forefront because the worldis using it.
(07:18):
So I think we all shouldunderstand a little bit more.
GLP1R agonists reduce hungersignals affecting melcoratin or
POMC and G AGRP pathways in thebrain.
We won't get into that.
That could be a whole hour abouthow those pathways work with
appetite and how we digest food.
(07:39):
But they they they reduce thehunger signals in the brain.
So you just feel less hungryeven after meals.
And blunt reward-driven eating.
It completely, you know, peopleare like, I don't even care for
the salty snacks in the evening.
I don't care about my sugarsweet tooth anymore.
I don't care about that stuff.
It lessens the wanting for highpalatable foods.
(08:02):
You lose that need to chew onthe chewy gummy or to um crunch
the crunchy chip or the cracker,you lose it.
All sounds good so far, right?
Which together reduce caloricintake overall, reduces
snacking, reduces all thesethings.
And you can see how you build alower calorie intake, which
helps people lose weight.
(08:23):
They also slow gastric emptying,sending stronger fullness
signals from the gut to thebrain.
So even with smaller portions ofmeals, you feel satiated, you
feel full, those signals get tothe brain, the brain's like,
yep, you ate enough.
That's good, we're good.
So there's a lot of stuff there.
There's evolving evidencecurrently that GLP1R agonists
can alter cravingslash addictioncircuits, which is why
(08:47):
researchers are studying themfor alcohol, nicotine, and other
substance use disorders,emerging area mechanisms still
under studies, and that's fromPMC.
So there is more research goinginto it.
They're using it for otherthings.
And the short history of Ozepic,Wagovi, and why this matters is
that Novo Nordisk's semaglutidewas first FDA approved as Ozepic
(09:10):
for type 2 diabetes officiallyin 2017.
Later, a higher dose formulationmarked as Wagobi was approved
specifically for chronic weightmanagement for obesity, people
at 31% or higher BMIs in 2021.
So it's Wagobi that has theobesity FDA approval and OZEP
(09:31):
that has the diabetic approval.
The diabetes approval notedweight loss as an observed
secondary benefit.
Subsequent trials led toobesity-specific approval
because it was secondary.
So they were controlling bloodsugar, A1C, and glucose as the
drug better, longer lasting, itwas as a better drug.
(09:51):
And they were like, listen,people are losing a ton of
weight, which makes sense.
So now it's blown up for weightloss.
But really, under insurancecode, still in the United
States, you have to be diagnosedwith either diabetes,
prediabetes, high A1C, oruncontrolled blood glucose
levels, so which is diabetes.
So that is how you get itcovered.
(10:12):
Otherwise, if you don't fallinto that bracket, it's out of
pocket through the peptide ways.
Other players like lyriclutide,axenotide, and the newer dual G
IPGLP1 agonists like terzepitideexpanded options.
Terzepicide showed very largeweight loss effects in obesity
(10:36):
trials for people 31% or higherin DMI, which accelerated public
attention to these drugs.
And that is the short history toit.
Underlying studies, both in theUnited States, Canada, and
Europe are showing that thebrain barriers that are being
blocked for addictivepersonalities transcend across
the brain through the mid-brainand brainstem, showing that any
(10:58):
type of behaviors can besuppressed.
So we're seeing this as inlibido being dropped, want
overall, desire going after thegoal.
You just see people kind of dulldown a little bit the longer
they use it.
And that's what I wanted tohighlight a little bit in this
podcast is like long-term use ofthese things alters the brain.
(11:21):
And you know, my stance on thebrain.
It was designed perfectly, wellbeyond anything we understand by
the universe or God, whateveryou believe, and it is perfect.
And if you keep messing with it,expect the side effects, expect
other things to happen.
Stop messing with your brains.
And we're going to see thisresearch down the road.
(11:41):
So that's a little bit, and Idon't have anything stamped on
you.
They're under it right now,they're showing it, and that's
why we're getting into nicotinealcoholic um studies is because
it is helping people kind ofdull down their need and
dependency for addictivebehaviors and eating and sugar
and salt and all these thingscan be addictive as well.
Sugar is more addictive thanmost drugs out there.
So we know this.
(12:02):
How do we use these properly?
Let's get into the practicalguidance of GLP1s.
And the indications from the FDAapproved way for you know T2D,
so various agents and chronicweight management in people
meeting obesity criteria likeBMI thresholds or BMI plus core
morbidity for Wagovie, useshould be supervised by a
(12:25):
clinician.
That's what the FDA guidelinesare.
You should not be buying this onyour own and dosing it on your
own.
Do not.
Do not, do not, do not, becauseit has to be monitored with
blood work and other things aswell.
The typical approach is to startlow and titrate slowly to reduce
GI side effects.
(12:46):
Nausea is the most common.
Weekly semi-glutide,semi-glutide injections have
established titration schedules,and clinicians should follow the
specific product label, and theywill for you, and based on your
weight and height and whatyou've done in the past.
There's some importantprinciples to remember with
GLP1s.
You've got to pair medicationwith lifestyle changes.
(13:07):
So diet, physical activity, andbehavior support improve
outcomes and are required forlong-term success.
The fundamentals can't go away.
You can't just keep eating fastfood and then go on on GLP1 and
say, oh, you know, I'm notlosing that much weight.
Why?
Well, we have to changeeverything.
Be mindful of other glucoselowering drugs, and that's why
clinicians have to be involved.
(13:27):
If you're on metformin, insulin,or anything else.
If a patient's on insulin orsulfonal urea, uh reduce doses
as needed to avoid hypoglycemia,and that's what your doctor's
gonna do, right?
So expect that weight trends tobe regained if medication is
stopped.
It says it right on the label.
Stop the medication, you'regonna get gain the weight back.
(13:48):
You got to treat GLP1 as achronic therapy when indicated
and plan follow-ups.
So it's either hyperacute, usedin like bodybuilding, athletics,
or something like that, to lowerbody fat percentage a little
bit.
They're using this.
I do I condone it, not so much,but if it's hyperacute, then
(14:09):
your body won't get used toanything long term, which I
approve.
Long-term use is where we runinto these issues.
Yes, you lose the 45 pounds overthe course of 12 months, and
then what happens when you getoff of this?
Well, those receptors start toawaken again.
What's gonna happen with that?
Do we fall back into old habits,which humans typically do, or
have we learned enough newskills to maintain that weight?
(14:32):
Could be, could be, butunfortunately, it's like 90%
fall back, 10% or less maintain.
Main risks and safety signals.
So I please listen to this ifyou're on it or you're thinking
about it.
These are the things I want youto walk away with today.
Common and expected sideeffects.
These are listed right on thebio.
Nausea, vomiting, constipation,diarrhea, early satiety, and
(14:55):
sometimes transient dizziness.
These are usually worse duringdose escalation because you're
just going to naturally not wantfood and eat less, and your
body's probably not used tothat.
Now we get into some crazystuff.
Pancreatitis.
Yes, we're blocking receptors inthe pancreas, which can make it
more inflamed because it'll backup other hormone pathways in
(15:18):
there as well.
Rare, but they are reported.
Pancreatitis, patients withsevere abdominal pain should
stop their NP and be evaluatedimmediately.
There should be no pain withthis.
Hunger pain, pangs, okay, but noorgan pain.
Gallbladder disease, rapidweight loss and GLP1 use are
associated with gallbladderevents like colobestasis, which
(15:40):
is gallbladder stones.
It can happen because you'reburning a lot of fat.
Your liver has to metabolize allthat fat loss that's happening.
There's a metabolist, there's ametabolism process to that as
well.
Your liver plays a role in that.
So all those extra triglyceridesbeing broken down, uh, great for
fat loss, but can back up thegallbladder a little bit too.
So that's purported in somecases.
(16:01):
Thyroid C cell tumors.
So it's a boxed warning.
Semaglutide has been boxedwarning based on rodent studies
showing medullary thyroidcarcinoma.
Human relevance is unclear, butsemaglutide is contraindicated
in people with a personal familyor history of medullary thyroid
(16:21):
carcinoma or M2 syndromes.
This is an important andprominent safety label item.
Kidney injuries.
Cause of acute kidney injurieshave been reported often related
to dehydration from GI sideeffects, monitor renal function,
especially in at-risk patients.
So if you've got renal issues,think twice about starting this.
(16:43):
Unapproved slash compoundedproducts.
That's probably the biggestthing we're running into in the
United States with all thecompounding pharmacies that have
been allowed to do this.
Use a reputable pharmacy thathas a good track record, and
hopefully your clinician isdoing that for you.
The FDA has warned aboutunimproved, unapproved
compounded GLP1 products anddirect to consumer vials that
(17:04):
may be unsafe or mislabeled.
Patients should avoid purchasingor using unapproved
formulations.
My biggest advice from what I'mseeing if you see anything super
cheap, stay away from it.
$59 a month,$100 a month.
There's no way a compoundingpharmacy can get it or make it
for that cheap.
So if you're seeing that, you'regetting you're probably getting
something not good.
(17:25):
So be careful on that.
And your clinician may or maynot know that.
Probably not if they're givingit to you.
No one out there wants to hurtother people and make just make
money.
Right?
Right?
Not America.
No way.
Monitor and monitoring and redflags.
Baseline.
Weights, your your baselineweights, your A1C, if you're
(17:48):
diabetic, I just check it oneveryone, A1C, a renal function,
medication list, thyroid slashhistory or family history, and
then counsel about GI sideeffects and when to seek care is
what you should see on yourfirst appointment with any
clinician.
You're doing this.
That's what they should beasking for.
They should be sending you fornew blood work, not using your
old blood work.
They can't because thingschange.
(18:09):
Have to see something new orrecent.
Monitor for persistent severe GIsymptoms.
That's your job.
If anything feels weird, emailthem, text them, call them
immediately, your provider.
Say, listen, I feel like this.
Severe abdominal pain, that'spancreatitis.
We talked about that.
Jaundice or signs ofcholecystitis, uh, gallbladder,
(18:30):
new thyroid nodules by palpatingyour throat if you feel any
nodules in there that aregetting bigger or anything, or
symptoms that are suggestive ofthyroid disease, review other
glucose medications to avoidhypoglycemia.
And that's your clinician's job.
So broader considerations aboutGLP1s, you know, access, ethics,
and how we're using them rightnow.
(18:50):
It's all vanity, of course.
That's how the world is rightnow.
It's all about how we lookinstead of how we actually
function, which I get.
It's supply and access is theissue right now.
So high demand has strainedsupplies in past years.
There are ethical concerns whenpeople without diabetes obtain
GLP1s for weight loss, whilepatients with diabetes may face
(19:12):
issues.
We saw that in 2024.
People with diabetes were notgetting the drug, not just
because of uh insurance denial,but because the drug was back
ordered.
Now, that's a problem.
You're taking something, it'slike almost like sweeping the
shelves off of uh uhantibiotics, taking all the
antibiotics off the shelf andbringing them home and be like,
(19:32):
I'm gonna save these for when myfamily needs it.
And then someone walks in rightafter you 10 minutes later with
a kid with an ear infection andthere's no antibiotics.
That's insane.
That's crazy that we're allowingthat.
But in America, we wouldn't putmoney over people, would we?
Or harm them, right?
(19:52):
Right?
Yeah.
Uh cost and insurance.
Many insurers cover GLP1s fordiabetes, coverage for obesity,
indications varies and can belimited.
And cost can be a barrier too.
These drugs aren't cheap.
The only way to get themapproved is to be diagnosed by a
medical doctor, your primaryphysician, that can diagnose you
(20:14):
for that diabetes, and that thiswould be a good uh drug to help
you.
Then you can get most of it, ifnot all of it, covered by
insurance.
Uh, body image and expectations,maintain realistic expectations
is what I tell all my patients.
Be realistic.
I will see men and women intheir 50s and 60s.
I ask them what's their goalweight, and they'll tell me
(20:34):
their goal weight.
I'll say, when was the last timeyou were like that?
And they're like, oh, 21.
Like literally college.
And I'm like, really?
You really think you can getback to college weight?
They're like, why not?
I should be able to do it.
I know why.
I'm in this position in thefirst place.
No, you can't get back to 21.
I'm sorry.
I'm just being completelyrealistic with you.
And if you do, you're gonna hurtyourself.
(20:56):
You're gonna you're gonnaactually drop a bunch of lean
muscle mass to get to thatnumber on the scale and then be
worse off than if you were 139versus 121 pounds when you were
21.
I just don't I don't get it.
So for clinicians and forpatients listening, you know,
GLP1 receptor agnes are powerfultools for glycemic control and
(21:17):
weight loss and usedappropriately under medical
supervision.
They work with pancreaticeffects by changing gut brain
signaling to reduce appetite andfood reward.
But they have side effects andimportant safety considerations.
Use appropriate screening,titration, and follow-ups to
make these things work for youthe best way possible.
(21:42):
So, a couple things.
Patient story, you know, that wehad a while, someone who used
the GLP one under medical care.
And in our office, we have ourfunctional medical program that
uh from two different doctorsthat are doing it and getting
results.
Patients do see the results, itmakes it easier when you lose
that appetite.
It just makes it easier to dothat.
(22:03):
We can't mistake in GLP1s forfat burners, they're not fat
burners.
What they do is help withabsorption, well, help with
emptying for absorption andsignal receptors from the gut to
the brain about being full ornot.
That's just really it.
They're blood glucose regulatorsby influencing the pancreas.
(22:26):
They're not fat burners, they'renot like um increasing heart
rate or caffeine or adrenalineor those some of those
supplements you take to increasebasal metabolic rate, which are
also dangerous in themselves,which are supposed to stimulate
metabolism and burning fat?
They're not that.
So by taking that in thebodybuilding world, I just don't
(22:47):
know what they're thinkingbecause it's not really
promoting that, it's reallypromoting their gut.
And these people that are thatathletic are already eating
well, they're on like a programof food.
So um interesting to see whatthe results are for them.
Does Ozepic cause everyone tolose muscle?
Myth or fact?
That was one that question thatcame up and actually spurred me
(23:08):
to do this episode.
Is it safe if I have a kidneydisease?
Um, those are those are twothings too.
So, number one, does Ozepiccause everyone to lose muscle?
If you keep doing what you'redoing today and you keep moving
forward, and 30 days from now,you you book an appointment and
you meet with a clinician andyou're put on GLP1, some
(23:29):
semaglutide, let's say, ortrzezepatite, and you start
using that and you continueliving the exact same life, no
real changes.
Will you lose muscle mass?
The answer is yes.
The only way to counteract that,because your your calories are
gonna go down, your eating isgonna go down, and your will to
(23:51):
do stuff is gonna go down.
You're just gonna kind of betaken down a little bit.
You'll be like, I don't I don'tcare.
I don't I don't care aboutwatching that movie, I don't
care about having sex, I don'tcare about like I just don't
care.
It's all gonna go down.
So if we don't start working outor start doing some resistance
training to offset the lowercalorie, our muscles are gonna
break down for protein use.
(24:12):
So, yes, the answer is yes.
So we talked, we saw thisozempic face, ozempic butt.
People are losing their glutes,they're losing their muscles in
their face because they justhaven't done anything.
They never did go to the gym,they've started GLP ones, and
they never started going to thegym.
They just continued living theirlife working at a desk, taking
that, losing the weight, but theweight's coming off everywhere.
(24:32):
So the biggest thing we'reseeing in and we do red light in
the office is skin.
More people are coming in forlike skin tightening than ever
before.
Like, I gotta lost all thisweight, I gotta tighten the
skin.
And the real answer to thatdramatic weight loss stuff is
there's no light in the world ormachine in the world that's
gonna really tighten the skinenough to make a dramatic
improvement.
(24:53):
That's gonna require uhliposuction and uh plastic
surgery.
It really is the only way to dothat.
So because of the fast weightloss there.
So those are some deaths.
Is it safe if I have kidneydisease?
The the fundamental answer isno, it's it's not safe.
If you have any type of kidneydisease, should be supervised by
a clinician.
And if a clinician is gonnastart you, I'd be a little weary
(25:15):
if you had kidney disease andsomeone said, Yeah, go ahead,
you can use GLP1s.
So, no, I would say no.
Um, that's it.
If you are considering GLP1s foryou, or you know someone in your
family that is, talk to aclinician first, make sure
they're reputable, check yourmedical history.
The biggest things are thyroidcancer and a family history of
(25:35):
it, and plan for slow doseescalation.
And that's typically howeveryone, all clinicians will
start you, and discuss otherdiabetes meds, if applicable, if
you're diabetic.
And commit to lifestyle support.
Avoid purchasing unapprovedcompound products online for a
cheaper price.
Don't do that.
Always do it through yourclinician, and you should be
(25:56):
pretty safe there.
What a world we live in.
This is the stuff we're talkingabout now.
One of the most popular things.
Look at go and Google search howmuch Ozempik has made.
Uh, is it Denmark or Norway?
I'm pretty sure it's Denmark.
Go go and look what it's done.
Like, it's just unbelievable.
I think they're all drivingFerraris in uh Denmark now, just
giving people Ferrari checks.
(26:16):
Like it's crazy.
Or whatever their sports car isin Denmark.
Do they make cars?
I don't think so.
They're not as cool as theItalians.
But um that's your podcast forthe week.
GLP1s, weight loss.
We'll do a whole weight lossseries again.
Healthy stuff, foods.
Uh, we've done diet stuff.
You can go back and search inour Living a Full Life.
Can you believe this is episodenumber 52 of our third season?
(26:40):
So this has been three years ofcontinuous podcasts every single
Tuesday for you and yourfamilies.
I'm not bragging, I'm justtelling you, it's not gonna
stop.
We're just gonna keep going,keeping you up to loop.
If you have any questions, thisis how I build podcasts.
So if you're wondering how Icome up with all these ideas and
how I can just talk for 20minutes every week, it's really
(27:03):
I do my research first on yourquestions, and I build podcasts
around that.
So they're relevant, and that'swhy we have listeners.
Stay well, stay healthy, takecare, and have a great week.
Welcome to another episode of Living a Full Life.
I'm Dr.
Enrico Dolcecori.
And each and every week we dropyou health and wellness tips for
you and your family to livehealthier, fuller lives by
listening in.
And we appreciate each and everyone of you.
This week's topic, GLP1s.
We're getting into weight lossseason.
You know what that means.
New Year's resolutions, end ofthe year.
(00:47):
It's actually sugar season.
And I thought this was a perfecttime to talk about this stuff
because people actually startthinking about this now.
This is almost the busiest timeof the year for people thinking
about weight loss.
I think it's from a healthyperspective, from our
perspective in the functionalmedicine and chiropractic realm,
is that we get healthy,conscious people that are always
ahead of the game.
So they're not going to waittill January 1st for a
(01:09):
resolution.
They know it's sugar season.
They're like, what can I do tostay out of trouble?
And that's a great preventativeway to keep yourself healthy.
And I love it.
So what a great timing for this.
GLP ones have blown up.
I think uh Ozempik alone has uhdoubled Denmark's gross national
product, I mean uh GDP.
(01:30):
That's insane, insane.
It's like trillion, I thinkwe're approaching trillions, uh,
kid with an S on uh how muchmoney this stuff is made at
Ozempic and its you knowcompounds as well.
So let's talk about what GLPones are.
And you know how what I'm gonnatalk about.
I'm gonna talk about thephysiology, how it works, what
it does in the body, so you geta general understanding because
(01:51):
that's how I understand things.
So I guess if you listen to mypodcast, it's because we are on
the same wavelength.
If you don't, it's because I'meither way above your head or
way maybe too dumb for you.
I don't know, whatever it is.
But the people who listen doappreciate it.
And I try and keep it simple buteducational each and every week.
This might be one you want toshare with people thinking about
GLP1s, some aglutides, on it,not on it, maybe had adverse
(02:14):
reactions, whatever may be.
We're gonna talk about thisdiving into GLP1s.
They are a class of medicinesthat has exploded into everyday
conversation.
Uh, we'll explain what they are,how they work in the body and
the brain, where they come from,even yes, the history of the
Ozempic story, how they shouldand shouldn't be used, and the
(02:35):
risk patients need to know aboutusing them.
Whether you treat patients,maybe you're a provider, or
maybe you're thinking aboutusing these themselves, or
you're just curious about them.
Could they be good for me?
Could they be good for someone Iknow?
This episode gives you thescience and the practical
takeaways that I hope you learnsome stuff from.
So, what is GLP1?
What does that stand for?
(02:56):
It's glucagon-like peptide dashone.
It's nor it's created in thebody naturally, it's an
incertain hormone released fromthe gut after you eat.
So it's in the lining of thegut, of your stomach, of your
gut.
Once you eat and you start thedigestive process, it releases
this hormone and it enhancesglucose-dependent insulin
(03:20):
secretions.
So it suppresses glucagon, slowsgastric emptying, and reduces
appetite.
And that's a good recipe forhelping people digest their
food, keep blood glucose levelsgood, lowering A1C, and eating
less.
And when you do those fourthings, you tend to lose weight.
(03:41):
It's a great side effect.
So we'll get into the storylater.
Physiological mechanism, ifyou're wondering how this works
in the nitty-gritty, they'resecreted from intestinal L cells
in response to nutrients likeendogenous GLP1 acts on GLP1
receptors in the pancreas toinsul increase insulin only when
(04:03):
glucose is elevated.
So for those of us that areinsulin sensitive, uh, this
helps because it tells thepancreas, hey, there's we're
helping, we're nudging you here.
Don't don't slack on theinsulin.
Um, because over time, as welive with higher glucose levels
in the blood, our pancreasstarts to get lethargic.
(04:23):
It gets fatigued, it gets tired,and then it's a little bit less
receptive to glucose.
And so it's like, uh, do wereally need to pump and inject
insulin?
I've been doing this for 48years.
Do I really need to keep pumpingevery time you eat a meal?
What's up with you and your andyour um jellies and marmalades
on your toast, man?
Like, come on, why do I gotta dothis every morning, right?
(04:45):
So that's what's going on withthe pancreas.
So it increases it, makes itmore sensitive, and says, yeah,
man, you gotta do it.
It's like a personal trainer foryour pancreas.
Like, come on, do it, do yourjob.
And it does it, but only whenit's elevated.
So we get better control.
That glucose dependence reduceshypoglycemia risk compared with
other older drugs that we usefor maybe diabetes or
(05:05):
prediabetes that would justinject insulin into the body.
And when you do that, you got tomonitor the glucose levels.
And if we do too much insulin,it will lower blood glucose to a
hypoglycemic level, which canmake people faint, pass out, and
those things.
So, this has been better atdoing that for pre-diabetic
patients, not for strictlydiabetic patients.
(05:26):
It also suppresses glucagonrelease and slows gastric
emptying, which helps reducepost-meal glucose spikes and
increase satiety, increases yourfeeling of feeling full.
So pharmaceutical GLP1 receptoragonists, exotide, uh,
(05:48):
lyriclutide, semaglutide, allthese ones are modified to last
longer in the body so they canbe dosed daily or weekly and
achieve sustained effects onappetite and glycemic control.
Okay, there you go.
That's the physiologicalmechanism.
All receptors in the gut and thepancreas to help control glucose
(06:12):
levels in the body bycontrolling good output of
insulin.
There you go.
That's a summary of thephysiology.
How did GLP once alter the brainand behavior?
This is stuff people don't talkabout.
We talk about the physiology, wetalk about what they do,
suppress appetite, helps emptythe gut, helps do all this
stuff, and helps you eat lessand you lose weight.
(06:33):
And everyone's I'll take it,I'll buy it.
How much is it?
600 bucks a month, I'll do it.
And they do it.
But the truth is, is what is itdoing to your brain?
If we're going to talk abouthormone receptors binding and
competing for receptor sites inthe body, you have to involve
the brain.
The brain is gonna get involvedwith this.
So GLP1 receptors are present inmultiple brain regions, not just
(06:57):
one.
Hypothalamus, your brain stem,your mesolithic reward circuits,
it's they're everywhere.
So these GLP1 receptors are backand forth.
The gut brain connection.
We've talked about this many,many times.
And this medication, this drug,this peptide, is bringing it to
the forefront because the worldis using it.
(07:18):
So I think we all shouldunderstand a little bit more.
GLP1R agonists reduce hungersignals affecting melcoratin or
POMC and G AGRP pathways in thebrain.
We won't get into that.
That could be a whole hour abouthow those pathways work with
appetite and how we digest food.
(07:39):
But they they they reduce thehunger signals in the brain.
So you just feel less hungryeven after meals.
And blunt reward-driven eating.
It completely, you know, peopleare like, I don't even care for
the salty snacks in the evening.
I don't care about my sugarsweet tooth anymore.
I don't care about that stuff.
It lessens the wanting for highpalatable foods.
(08:02):
You lose that need to chew onthe chewy gummy or to um crunch
the crunchy chip or the cracker,you lose it.
All sounds good so far, right?
Which together reduce caloricintake overall, reduces
snacking, reduces all thesethings.
And you can see how you build alower calorie intake, which
helps people lose weight.
(08:23):
They also slow gastric emptying,sending stronger fullness
signals from the gut to thebrain.
So even with smaller portions ofmeals, you feel satiated, you
feel full, those signals get tothe brain, the brain's like,
yep, you ate enough.
That's good, we're good.
So there's a lot of stuff there.
There's evolving evidencecurrently that GLP1R agonists
can alter cravingslash addictioncircuits, which is why
(08:47):
researchers are studying themfor alcohol, nicotine, and other
substance use disorders,emerging area mechanisms still
under studies, and that's fromPMC.
So there is more research goinginto it.
They're using it for otherthings.
And the short history of Ozepic,Wagovi, and why this matters is
that Novo Nordisk's semaglutidewas first FDA approved as Ozepic
(09:10):
for type 2 diabetes officiallyin 2017.
Later, a higher dose formulationmarked as Wagobi was approved
specifically for chronic weightmanagement for obesity, people
at 31% or higher BMIs in 2021.
So it's Wagobi that has theobesity FDA approval and OZEP
(09:31):
that has the diabetic approval.
The diabetes approval notedweight loss as an observed
secondary benefit.
Subsequent trials led toobesity-specific approval
because it was secondary.
So they were controlling bloodsugar, A1C, and glucose as the
drug better, longer lasting, itwas as a better drug.
(09:51):
And they were like, listen,people are losing a ton of
weight, which makes sense.
So now it's blown up for weightloss.
But really, under insurancecode, still in the United
States, you have to be diagnosedwith either diabetes,
prediabetes, high A1C, oruncontrolled blood glucose
levels, so which is diabetes.
So that is how you get itcovered.
(10:12):
Otherwise, if you don't fallinto that bracket, it's out of
pocket through the peptide ways.
Other players like lyriclutide,axenotide, and the newer dual G
IPGLP1 agonists like terzepitideexpanded options.
Terzepicide showed very largeweight loss effects in obesity
(10:36):
trials for people 31% or higherin DMI, which accelerated public
attention to these drugs.
And that is the short history toit.
Underlying studies, both in theUnited States, Canada, and
Europe are showing that thebrain barriers that are being
blocked for addictivepersonalities transcend across
the brain through the mid-brainand brainstem, showing that any
(10:58):
type of behaviors can besuppressed.
So we're seeing this as inlibido being dropped, want
overall, desire going after thegoal.
You just see people kind of dulldown a little bit the longer
they use it.
And that's what I wanted tohighlight a little bit in this
podcast is like long-term use ofthese things alters the brain.
(11:21):
And you know, my stance on thebrain.
It was designed perfectly, wellbeyond anything we understand by
the universe or God, whateveryou believe, and it is perfect.
And if you keep messing with it,expect the side effects, expect
other things to happen.
Stop messing with your brains.
And we're going to see thisresearch down the road.
(11:41):
So that's a little bit, and Idon't have anything stamped on
you.
They're under it right now,they're showing it, and that's
why we're getting into nicotinealcoholic um studies is because
it is helping people kind ofdull down their need and
dependency for addictivebehaviors and eating and sugar
and salt and all these thingscan be addictive as well.
Sugar is more addictive thanmost drugs out there.
So we know this.
(12:02):
How do we use these properly?
Let's get into the practicalguidance of GLP1s.
And the indications from the FDAapproved way for you know T2D,
so various agents and chronicweight management in people
meeting obesity criteria likeBMI thresholds or BMI plus core
morbidity for Wagovie, useshould be supervised by a
(12:25):
clinician.
That's what the FDA guidelinesare.
You should not be buying this onyour own and dosing it on your
own.
Do not.
Do not, do not, do not, becauseit has to be monitored with
blood work and other things aswell.
The typical approach is to startlow and titrate slowly to reduce
GI side effects.
(12:46):
Nausea is the most common.
Weekly semi-glutide,semi-glutide injections have
established titration schedules,and clinicians should follow the
specific product label, and theywill for you, and based on your
weight and height and whatyou've done in the past.
There's some importantprinciples to remember with
GLP1s.
You've got to pair medicationwith lifestyle changes.
(13:07):
So diet, physical activity, andbehavior support improve
outcomes and are required forlong-term success.
The fundamentals can't go away.
You can't just keep eating fastfood and then go on on GLP1 and
say, oh, you know, I'm notlosing that much weight.
Why?
Well, we have to changeeverything.
Be mindful of other glucoselowering drugs, and that's why
clinicians have to be involved.
(13:27):
If you're on metformin, insulin,or anything else.
If a patient's on insulin orsulfonal urea, uh reduce doses
as needed to avoid hypoglycemia,and that's what your doctor's
gonna do, right?
So expect that weight trends tobe regained if medication is
stopped.
It says it right on the label.
Stop the medication, you'regonna get gain the weight back.
(13:48):
You got to treat GLP1 as achronic therapy when indicated
and plan follow-ups.
So it's either hyperacute, usedin like bodybuilding, athletics,
or something like that, to lowerbody fat percentage a little
bit.
They're using this.
I do I condone it, not so much,but if it's hyperacute, then
(14:09):
your body won't get used toanything long term, which I
approve.
Long-term use is where we runinto these issues.
Yes, you lose the 45 pounds overthe course of 12 months, and
then what happens when you getoff of this?
Well, those receptors start toawaken again.
What's gonna happen with that?
Do we fall back into old habits,which humans typically do, or
have we learned enough newskills to maintain that weight?
(14:32):
Could be, could be, butunfortunately, it's like 90%
fall back, 10% or less maintain.
Main risks and safety signals.
So I please listen to this ifyou're on it or you're thinking
about it.
These are the things I want youto walk away with today.
Common and expected sideeffects.
These are listed right on thebio.
Nausea, vomiting, constipation,diarrhea, early satiety, and
(14:55):
sometimes transient dizziness.
These are usually worse duringdose escalation because you're
just going to naturally not wantfood and eat less, and your
body's probably not used tothat.
Now we get into some crazystuff.
Pancreatitis.
Yes, we're blocking receptors inthe pancreas, which can make it
more inflamed because it'll backup other hormone pathways in
(15:18):
there as well.
Rare, but they are reported.
Pancreatitis, patients withsevere abdominal pain should
stop their NP and be evaluatedimmediately.
There should be no pain withthis.
Hunger pain, pangs, okay, but noorgan pain.
Gallbladder disease, rapidweight loss and GLP1 use are
associated with gallbladderevents like colobestasis, which
(15:40):
is gallbladder stones.
It can happen because you'reburning a lot of fat.
Your liver has to metabolize allthat fat loss that's happening.
There's a metabolist, there's ametabolism process to that as
well.
Your liver plays a role in that.
So all those extra triglyceridesbeing broken down, uh, great for
fat loss, but can back up thegallbladder a little bit too.
So that's purported in somecases.
(16:01):
Thyroid C cell tumors.
So it's a boxed warning.
Semaglutide has been boxedwarning based on rodent studies
showing medullary thyroidcarcinoma.
Human relevance is unclear, butsemaglutide is contraindicated
in people with a personal familyor history of medullary thyroid
(16:21):
carcinoma or M2 syndromes.
This is an important andprominent safety label item.
Kidney injuries.
Cause of acute kidney injurieshave been reported often related
to dehydration from GI sideeffects, monitor renal function,
especially in at-risk patients.
So if you've got renal issues,think twice about starting this.
(16:43):
Unapproved slash compoundedproducts.
That's probably the biggestthing we're running into in the
United States with all thecompounding pharmacies that have
been allowed to do this.
Use a reputable pharmacy thathas a good track record, and
hopefully your clinician isdoing that for you.
The FDA has warned aboutunimproved, unapproved
compounded GLP1 products anddirect to consumer vials that
(17:04):
may be unsafe or mislabeled.
Patients should avoid purchasingor using unapproved
formulations.
My biggest advice from what I'mseeing if you see anything super
cheap, stay away from it.
$59 a month,$100 a month.
There's no way a compoundingpharmacy can get it or make it
for that cheap.
So if you're seeing that, you'regetting you're probably getting
something not good.
(17:25):
So be careful on that.
And your clinician may or maynot know that.
Probably not if they're givingit to you.
No one out there wants to hurtother people and make just make
money.
Right?
Right?
Not America.
No way.
Monitor and monitoring and redflags.
Baseline.
Weights, your your baselineweights, your A1C, if you're
(17:48):
diabetic, I just check it oneveryone, A1C, a renal function,
medication list, thyroid slashhistory or family history, and
then counsel about GI sideeffects and when to seek care is
what you should see on yourfirst appointment with any
clinician.
You're doing this.
That's what they should beasking for.
They should be sending you fornew blood work, not using your
old blood work.
They can't because thingschange.
(18:09):
Have to see something new orrecent.
Monitor for persistent severe GIsymptoms.
That's your job.
If anything feels weird, emailthem, text them, call them
immediately, your provider.
Say, listen, I feel like this.
Severe abdominal pain, that'spancreatitis.
We talked about that.
Jaundice or signs ofcholecystitis, uh, gallbladder,
(18:30):
new thyroid nodules by palpatingyour throat if you feel any
nodules in there that aregetting bigger or anything, or
symptoms that are suggestive ofthyroid disease, review other
glucose medications to avoidhypoglycemia.
And that's your clinician's job.
So broader considerations aboutGLP1s, you know, access, ethics,
and how we're using them rightnow.
(18:50):
It's all vanity, of course.
That's how the world is rightnow.
It's all about how we lookinstead of how we actually
function, which I get.
It's supply and access is theissue right now.
So high demand has strainedsupplies in past years.
There are ethical concerns whenpeople without diabetes obtain
GLP1s for weight loss, whilepatients with diabetes may face
(19:12):
issues.
We saw that in 2024.
People with diabetes were notgetting the drug, not just
because of uh insurance denial,but because the drug was back
ordered.
Now, that's a problem.
You're taking something, it'slike almost like sweeping the
shelves off of uh uhantibiotics, taking all the
antibiotics off the shelf andbringing them home and be like,
(19:32):
I'm gonna save these for when myfamily needs it.
And then someone walks in rightafter you 10 minutes later with
a kid with an ear infection andthere's no antibiotics.
That's insane.
That's crazy that we're allowingthat.
But in America, we wouldn't putmoney over people, would we?
Or harm them, right?
(19:52):
Right?
Yeah.
Uh cost and insurance.
Many insurers cover GLP1s fordiabetes, coverage for obesity,
indications varies and can belimited.
And cost can be a barrier too.
These drugs aren't cheap.
The only way to get themapproved is to be diagnosed by a
medical doctor, your primaryphysician, that can diagnose you
(20:14):
for that diabetes, and that thiswould be a good uh drug to help
you.
Then you can get most of it, ifnot all of it, covered by
insurance.
Uh, body image and expectations,maintain realistic expectations
is what I tell all my patients.
Be realistic.
I will see men and women intheir 50s and 60s.
I ask them what's their goalweight, and they'll tell me
(20:34):
their goal weight.
I'll say, when was the last timeyou were like that?
And they're like, oh, 21.
Like literally college.
And I'm like, really?
You really think you can getback to college weight?
They're like, why not?
I should be able to do it.
I know why.
I'm in this position in thefirst place.
No, you can't get back to 21.
I'm sorry.
I'm just being completelyrealistic with you.
And if you do, you're gonna hurtyourself.
(20:56):
You're gonna you're gonnaactually drop a bunch of lean
muscle mass to get to thatnumber on the scale and then be
worse off than if you were 139versus 121 pounds when you were
21.
I just don't I don't get it.
So for clinicians and forpatients listening, you know,
GLP1 receptor agnes are powerfultools for glycemic control and
(21:17):
weight loss and usedappropriately under medical
supervision.
They work with pancreaticeffects by changing gut brain
signaling to reduce appetite andfood reward.
But they have side effects andimportant safety considerations.
Use appropriate screening,titration, and follow-ups to
make these things work for youthe best way possible.
(21:42):
So, a couple things.
Patient story, you know, that wehad a while, someone who used
the GLP one under medical care.
And in our office, we have ourfunctional medical program that
uh from two different doctorsthat are doing it and getting
results.
Patients do see the results, itmakes it easier when you lose
that appetite.
It just makes it easier to dothat.
(22:03):
We can't mistake in GLP1s forfat burners, they're not fat
burners.
What they do is help withabsorption, well, help with
emptying for absorption andsignal receptors from the gut to
the brain about being full ornot.
That's just really it.
They're blood glucose regulatorsby influencing the pancreas.
(22:26):
They're not fat burners, they'renot like um increasing heart
rate or caffeine or adrenalineor those some of those
supplements you take to increasebasal metabolic rate, which are
also dangerous in themselves,which are supposed to stimulate
metabolism and burning fat?
They're not that.
So by taking that in thebodybuilding world, I just don't
(22:47):
know what they're thinkingbecause it's not really
promoting that, it's reallypromoting their gut.
And these people that are thatathletic are already eating
well, they're on like a programof food.
So um interesting to see whatthe results are for them.
Does Ozepic cause everyone tolose muscle?
Myth or fact?
That was one that question thatcame up and actually spurred me
(23:08):
to do this episode.
Is it safe if I have a kidneydisease?
Um, those are those are twothings too.
So, number one, does Ozepiccause everyone to lose muscle?
If you keep doing what you'redoing today and you keep moving
forward, and 30 days from now,you you book an appointment and
you meet with a clinician andyou're put on GLP1, some
(23:29):
semaglutide, let's say, ortrzezepatite, and you start
using that and you continueliving the exact same life, no
real changes.
Will you lose muscle mass?
The answer is yes.
The only way to counteract that,because your your calories are
gonna go down, your eating isgonna go down, and your will to
(23:51):
do stuff is gonna go down.
You're just gonna kind of betaken down a little bit.
You'll be like, I don't I don'tcare.
I don't I don't care aboutwatching that movie, I don't
care about having sex, I don'tcare about like I just don't
care.
It's all gonna go down.
So if we don't start working outor start doing some resistance
training to offset the lowercalorie, our muscles are gonna
break down for protein use.
(24:12):
So, yes, the answer is yes.
So we talked, we saw thisozempic face, ozempic butt.
People are losing their glutes,they're losing their muscles in
their face because they justhaven't done anything.
They never did go to the gym,they've started GLP ones, and
they never started going to thegym.
They just continued living theirlife working at a desk, taking
that, losing the weight, but theweight's coming off everywhere.
(24:32):
So the biggest thing we'reseeing in and we do red light in
the office is skin.
More people are coming in forlike skin tightening than ever
before.
Like, I gotta lost all thisweight, I gotta tighten the
skin.
And the real answer to thatdramatic weight loss stuff is
there's no light in the world ormachine in the world that's
gonna really tighten the skinenough to make a dramatic
improvement.
(24:53):
That's gonna require uhliposuction and uh plastic
surgery.
It really is the only way to dothat.
So because of the fast weightloss there.
So those are some deaths.
Is it safe if I have kidneydisease?
The the fundamental answer isno, it's it's not safe.
If you have any type of kidneydisease, should be supervised by
a clinician.
And if a clinician is gonnastart you, I'd be a little weary
(25:15):
if you had kidney disease andsomeone said, Yeah, go ahead,
you can use GLP1s.
So, no, I would say no.
Um, that's it.
If you are considering GLP1s foryou, or you know someone in your
family that is, talk to aclinician first, make sure
they're reputable, check yourmedical history.
The biggest things are thyroidcancer and a family history of
(25:35):
it, and plan for slow doseescalation.
And that's typically howeveryone, all clinicians will
start you, and discuss otherdiabetes meds, if applicable, if
you're diabetic.
And commit to lifestyle support.
Avoid purchasing unapprovedcompound products online for a
cheaper price.
Don't do that.
Always do it through yourclinician, and you should be
(25:56):
pretty safe there.
What a world we live in.
This is the stuff we're talkingabout now.
One of the most popular things.
Look at go and Google search howmuch Ozempik has made.
Uh, is it Denmark or Norway?
I'm pretty sure it's Denmark.
Go go and look what it's done.
Like, it's just unbelievable.
I think they're all drivingFerraris in uh Denmark now, just
giving people Ferrari checks.
(26:16):
Like it's crazy.
Or whatever their sports car isin Denmark.
Do they make cars?
I don't think so.
They're not as cool as theItalians.
But um that's your podcast forthe week.
GLP1s, weight loss.
We'll do a whole weight lossseries again.
Healthy stuff, foods.
Uh, we've done diet stuff.
You can go back and search inour Living a Full Life.
Can you believe this is episodenumber 52 of our third season?
(26:40):
So this has been three years ofcontinuous podcasts every single
Tuesday for you and yourfamilies.
I'm not bragging, I'm justtelling you, it's not gonna
stop.
We're just gonna keep going,keeping you up to loop.
If you have any questions, thisis how I build podcasts.
So if you're wondering how Icome up with all these ideas and
how I can just talk for 20minutes every week, it's really
(27:03):
I do my research first on yourquestions, and I build podcasts
around that.
So they're relevant, and that'swhy we have listeners.
Stay well, stay healthy, takecare, and have a great week.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Las Culturistas with Matt Rogers and Bowen Yang
Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.
Crime Junkie
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by audiochuck Media Company.